Novavax, Inc. (NASDAQ:NVAX) recently saw its volume around 3.27 million shares and on average it trades 6.36 million shares a day. The opening price of $1.17, led it to gain 0.86% to reach $1.17 upon the closing bell.Novavax, Inc. (NVAX) Analyst Opinion
Novavax, Inc. has a consensus hold rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 18.69% of shares outstanding. The stock spiked 1.74% last month and is down -7.14 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover NVAX having a buy-equivalent rating. Analysts have placed a $1.55 price target on Novavax, Inc., suggesting a 32.48% gain from recent close. It’s currently trading about -39.38% below its 52-week high.Novavax, Inc. Earnings Surprise
Novavax, Inc. (NVAX) failed to surprise the stock market in its last reported earnings when it earned -$0.16 a piece versus the consensus-estimated -$0.16. Its revenue totaled $6.3 million up 10.92% from the previous quarter.
This stock (NVAX) is ahead of its 52-week low with 60.27%. Its last month’s stock price volatility remained 3.36% which for the week stands at 4.14%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.12% and stays 7.83% away from its 50 days moving average. Over the last five days, shares have managed 1.74% gains and now is up 0.68% since hitting its 200-day moving average of $1.06. Novavax, Inc. (NVAX) has made its way to a 12-month decline of -37.77%.
Turning to Clovis Oncology, Inc. (NASDAQ:CLVS), its shares were trading at $82.82 a retreat of $-0.68, on the trading floor. The stock, after opening at $84.14, touched a high of $84.51 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Clovis Oncology, Inc. has 4 buy ratings, 4 holds and 0 sells even after the stock tumbled -16.72% from its high of $99.45 to a $3.99 billion market value through last close.Clovis Oncology, Inc. (CLVS) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.07 to 2 during a month. Analysts set a 12-month price target of $93.73 a share. The target implies a 13.17% spike from where the shares are currently trading. Also, the current price highlights a discount of 50.93% to analysts’ high consensus price target.Clovis Oncology, Inc. (NASDAQ:CLVS) Intraday Trading
The counter witnessed a trading volume of 0.94 million shares versus an average volume of 1.65 million shares during last trading session. Its last month’s stock price volatility remained 3.65% which for the week approaches 4.99%. The lowest price the stock reached in the last trading day was $81.57 and compares with the $25.5 52-week low. The stock recovered 220.88% since its low point and has performed 86.45% year-to-date.